Synonyms: PX-866 | PX866
Compound class:
Synthetic organic
Comment: Sonolisib is a small-molecule wortmannin inhibitor of the alpha, gamma, and delta isoforms of phosphoinositide 3-kinase (PI3K) with potential antineoplastic activity [1]. It is compound 4 in Zask et al. (2008) [3].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Several Phase 2 clinical trials in solid tumour types including advanced BRAF-mutant melanomas, non-small cell lung cancer (NSCLC), squamous cell head and neck cancer, prostate cancer and glioblastoma have been completed, but as of October 2018 there are no active studies listed by ClinicalTrials.gov. Click here to link to ClinicalTrials.gov's complete list of PX-866 trials. |
Mechanism Of Action and Pharmacodynamic Effects |
Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents. Inhibition of PI3K-induced activation of this pathway by sonolisib, may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations [2]. |